ESMO 2019 | BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO

Hope Rugo, MD, FASCO, UCSF Comprehensive Cancer Center, San Diego, CA, discusses the BYLieve study (NCT03056755), which will add to the data accrued on alpelisib in the SOLAR-1 study where few patients had prior CDK4/6 inhibitor treatment. This ongoing phase 2, multicenter, open-label, noncomparative study is assessing alpelisib plus endocrine therapy (fulvestrant or letrozole) in patients with PIK3CA-mutated HR+/HER2- advanced breast cancer who progressed on or after prior treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.